Onconetix, Inc. (ONCO)
0.4788
-0.07
(-12.63%)
USD |
NASDAQ |
Oct 16, 16:00
0.5301
+0.05
(+10.71%)
After-Hours: 20:00
Onconetix Net Income (Quarterly) : -2.867M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.867M |
| March 31, 2026 | -4.215M |
| December 31, 2025 | 5.670M |
| September 30, 2025 | -8.784M |
| June 30, 2025 | -2.372M |
| March 31, 2025 | -8.546M |
| December 31, 2024 | -29.44M |
| September 30, 2024 | -3.827M |
| June 30, 2024 | -14.31M |
| March 31, 2024 | -11.12M |
| December 31, 2023 | -22.35M |
| September 30, 2023 | -5.347M |
| Date | Value |
|---|---|
| June 30, 2023 | -6.865M |
| March 31, 2023 | -2.847M |
| December 31, 2022 | -3.218M |
| September 30, 2022 | -3.867M |
| June 30, 2022 | -4.265M |
| March 31, 2022 | -2.071M |
| December 31, 2021 | -1.203M |
| September 30, 2021 | -1.096M |
| March 31, 2021 | -0.3258M |
| December 31, 2020 | -0.4044M |
| September 30, 2020 | -0.3344M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vistagen Therapeutics, Inc. | -13.03M |
| BridgeBio Pharma, Inc. | -155.89M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.0171M |
| Total Expenses (Quarterly) | 2.884M |
| EPS Diluted (Quarterly) | -1.278 |
| Enterprise Value | -3.937M |
| Gross Profit Margin (Quarterly) | 25.15% |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -41.58K% |
| Normalized Earnings Yield | -53222.20 |